Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Disease 1Cardiovascular Diseases 1

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Prednisone 5Mammography 5Colonoscopy 5Biopsy 5Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Lenalidomide 4Biopsy, Fine-Needle 4pembrolizumab 3Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Melphalan 3Liquid Biopsy 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Urination 2Preoperative Exercise 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × glycidol × Clear all
NCT05930626 2023-07-05

Biomarkers of Acrylamide, Glycidol, POPs, PFAS and Disease Outcomes and OMICs Signatures

Karolinska Institutet

Completed
9,254 enrolled

Cardiovascular Diseases, Disease, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡